Tcr2 Therapeutics Price Prediction
| TCRRDelisted Stock | USD 1.48 0.00 0.00% |
Oversold Vs Overbought
57
Oversold | Overbought |
Using Tcr2 Therapeutics hype-based prediction, you can estimate the value of Tcr2 Therapeutics from the perspective of Tcr2 Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Tcr2 Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Tcr2 because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Tcr2 Therapeutics after-hype prediction price | USD 1.48 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as delisted stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Tcr2 |
Tcr2 Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Tcr2 Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Tcr2 Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Tcr2 Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Tcr2 Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Tcr2 Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Tcr2 Therapeutics' historical news coverage. Tcr2 Therapeutics' after-hype downside and upside margins for the prediction period are 1.48 and 1.48, respectively. We have considered Tcr2 Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Tcr2 Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of Tcr2 Therapeutics is based on 3 months time horizon.
Tcr2 Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Tcr2 Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tcr2 Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Delisted Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Tcr2 Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 0.00 | 0.00 | 0.00 | 8 Events / Month | 7 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.48 | 1.48 | 0.00 |
|
Tcr2 Therapeutics Hype Timeline
Tcr2 Therapeutics is at this time traded for 1.48. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Tcr2 is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is projected to be very small, whereas the daily expected return is at this time at 0.0%. %. The volatility of related hype on Tcr2 Therapeutics is about 0.0%, with the expected price after the next announcement by competition of 1.48. About 54.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.22. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tcr2 Therapeutics recorded a loss per share of 4.2. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be in about 8 days. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.Tcr2 Therapeutics Related Hype Analysis
Having access to credible news sources related to Tcr2 Therapeutics' direct competition is more important than ever and may enhance your ability to predict Tcr2 Therapeutics' future price movements. Getting to know how Tcr2 Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Tcr2 Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| AFMD | Affimed NV | 0.42 | 8 per month | 0.00 | (0.20) | 6.39 | (6.82) | 21.26 | |
| PIRS | Pieris Pharmaceuticals | 0.25 | 5 per month | 0.00 | (0.11) | 3.23 | (3.40) | 12.92 | |
| ADCT | ADC Therapeutics SA | 0.03 | 9 per month | 0.00 | (0.12) | 6.98 | (7.81) | 22.87 | |
| AGEN | Agenus Inc | (0.12) | 9 per month | 0.00 | (0.14) | 6.59 | (8.60) | 27.05 | |
| RVMD | Revolution Medicines | 1.13 | 10 per month | 2.04 | 0.12 | 4.81 | (3.24) | 10.95 | |
| BDTX | Black Diamond Therapeutics | 0.18 | 7 per month | 0.00 | (0.30) | 5.56 | (8.30) | 19.51 | |
| BCEL | Atreca Inc | 0.00 | 0 per month | 5.00 | 0.01 | 7.53 | (9.65) | 23.80 | |
| PASG | Passage Bio | (0.02) | 8 per month | 0.00 | (0.08) | 9.33 | (9.88) | 25.50 | |
| HARP | Harpoon Therapeutics | 0.00 | 0 per month | 3.28 | 0.09 | 9.59 | (6.25) | 22.48 | |
| ALEC | Alector | 0.1 | 8 per month | 0.00 | (0.07) | 8.66 | (7.89) | 26.60 | |
| FIXX | Homology Medicines | (0.01) | 2 per month | 3.52 | 0.01 | 5.77 | (5.61) | 19.43 | |
| STOK | Stoke Therapeutics | (0.04) | 10 per month | 0.00 | (0.09) | 4.68 | (6.99) | 21.35 |
Tcr2 Therapeutics Additional Predictive Modules
Most predictive techniques to examine Tcr2 price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Tcr2 using various technical indicators. When you analyze Tcr2 charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Tcr2 Therapeutics Predictive Indicators
The successful prediction of Tcr2 Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Tcr2 Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Tcr2 Therapeutics based on analysis of Tcr2 Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Tcr2 Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Tcr2 Therapeutics's related companies.
Story Coverage note for Tcr2 Therapeutics
The number of cover stories for Tcr2 Therapeutics depends on current market conditions and Tcr2 Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Tcr2 Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Tcr2 Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Tcr2 Therapeutics Short Properties
Tcr2 Therapeutics' future price predictability will typically decrease when Tcr2 Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Tcr2 Therapeutics often depends not only on the future outlook of the potential Tcr2 Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Tcr2 Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 38.6 M | |
| Cash And Short Term Investments | 149.2 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |